Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesTwo-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program
The American Journal of Cardiology, 06/22/09
Lasala JM et al. – Results suggest that TAXUS paclitaxel-eluting stents abrogate the increased diabetic risk of clinical restenosis previously reported with bare metal stents, with similar low risk of myocardial infarction or stent thrombosis for diabetic and nondiabetic pts. However, 2-yr mortality risk is still increased in diabetic pts.
Methods- Study of whether paclitaxel provides equivalent revascularization decrease in diabetic and nondiabetic pts
- ARRIVE registries; 7,492 pts receiving TAXUS Express stents, including 2,112 with medically treated diabetes
- Comparison of results with remaining 5,380 nondiabetic pts
- Comparable 2-yr target lesion revascularization (TLR) in diabetic vs nondiabetic pts (8.2% vs 7.7%)
- Similar TLR after multivariate adjustment for baseline differences (7.1% vs 6.8%)
- No significant TLR differences between diabetic vs nondiabetic pts with small vessels (9.7% vs 9.5%) or left main coronary artery, 3-vessel, or bifurcation stenting (10.7% vs 13.1%)
- Diabetes not a significant TLR predictor
- Stent thrombosis (2.6% vs 2.4%) and myocardial infarction (3.8% vs 3.0%) rates similar for diabetic vs nondiabetic pts
- Significantly increased 2-yr mortality for diabetic vs nondiabetic pts (9.7% vs 5.3%); thus significantly increased major cardiac events in diabetic pts
- No difference in stent-related major cardiac events (8.9% vs 10.1%)
Today in Interventional...keeping you current
Receive free subspecialty "5-minute updates" via email
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Carotid artery stenting vs. endarterectomy
European Heart Journal, 10/30/09
Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation
Europace, 10/15/09
Sponsor
Article Search
Sponsor
Sponsor